WO 2005/069731 -19- PCT/IL2005/000078

## **CLAIMS**

1. A composition for ameliorating, treating, and preventing aphthous stomatitis and oral mucositis, comprising a quinoline derivative of formula I:

$$(R_1)_{q} \qquad \qquad (R_1)_{p}$$
 
$$R_2 \qquad \qquad I$$

or a pharmaceutically acceptable salt thereof, wherein

R<sub>1</sub> and R<sub>1</sub>' are independently selected from -H, -Cl, -F, C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkyloxy, and -CF<sub>3</sub>;

R<sub>2</sub> and R<sub>2</sub>' are independently selected from -H, -NH(R<sub>3</sub>), and -C(OH)(R<sub>3</sub>), wherein R<sub>3</sub> is selected from phenyl and C<sub>3</sub>-C<sub>6</sub> alkyl, substituted with 1 to 3 substituents selected from C<sub>1</sub>-C<sub>2</sub> alkyl, ethenyl, -OH, and -NH<sub>2</sub>, and wherein said -NH<sub>2</sub> is either optionally substituted with one or two groups selected from ethyl and hydroxyethyl, or the nitrogen atom of said -NH<sub>2</sub> is connected with 1 or 2 carbon atoms of said C<sub>3</sub>-C<sub>6</sub> alkyl or C<sub>1</sub>-C<sub>2</sub> alkyl, possibly forming bicyclic structure;

p is an integer from 1 to 3; and q is an integer from 1 to 4.

- 2. A composition according to claim 1, further comprising an antiseptic.
- 3. A composition according to claim 2, wherein said antiseptic is selected from the group consisting of chlorhexidine, thymol, and esters of phydroxybenzoic acid selected from methyl, ethyl, propyl, and butyl.
- 4. A composition according to claim 1 or 2, further comprising a constituent selected from solvents, buffers, carriers, binding agents, stabilizers, adjuvants, diluents, excipients, surfactants, flavors, and odorants.

- 5. A composition according to claim 1 or 2, further comprising another pharmaceutically active substance selected from analysesic, anti-inflammatory, antiviral, antibacterial, antifungal, antiseptic, and antineoplastic compounds.
- 6. A composition according to claim 2, wherein said antiseptic and quinoline derivative are applied subsequently, in any order.
- 7. A composition according to claim 2, wherein said antiseptic and quinoline derivative are applied simultaneously.
- 8. A composition according to claim 1 or 2, for topical use.
- 9. A composition according to claim 1, for oral delivery.
- 10. A composition according to claim 8, wherein said use comprises rinsing with liquid, or applying cream, ointment, gel, patch, or spray.
- 11. A composition according to any one of claims 1 to 10, wherein said stomatitis or mucositis comprises canker sores associated with aphtha minor, aphtha major, recurrent aphthous ulcers (RAU), recurrent aphthous stomatitis (RAS), herpetiform aphthae, vesicular-bullous erosive or ulcerative lesions, pemphigus family disorders, pemphigoid family disorders, linear IgA disorders or other immunoregulatory disorders, herpetiform dermatitis, discoid lupus erythematosus, radiotherapeutic mucositis, or chemotherapeutic mucositis.
- 12. A composition according to claim 11, wherein said mucositis or stomatitis is accompanied by a secondary infection.
- 13. A composition according to any one of claims 1 to 12, wherein in said quinoline derivative of formula I, as defined in claim 1,

WO 2005/069731 -21- PCT/IL2005/000078

R<sub>1</sub> and R<sub>1</sub>' are independently selected from -Cl, -OCH<sub>3</sub>, and -CF<sub>3</sub>; one of R<sub>2</sub> and R<sub>2</sub>' is -H, and one of R<sub>2</sub> and R<sub>2</sub>' is selected from -NH(R<sub>3</sub>), and -C(OH)(R<sub>3</sub>), wherein R<sub>3</sub> is selected from phenyl and C<sub>3</sub>-C<sub>5</sub> alkyl, substituted with 1 to 2 substituents selected from C<sub>1</sub>-C<sub>2</sub> alkyl, ethenyl, and -NH<sub>2</sub>, and wherein either said -NH<sub>2</sub> is optionally substituted with one or two groups selected from ethyl and hydroxyethyl, or the nitrogen atom of said -NH<sub>2</sub> is connected with 1 or 2 carbon atoms of said C<sub>3</sub>-C<sub>5</sub> alkyl or C<sub>1</sub>-C<sub>2</sub> alkyl, possibly forming bicyclic structure; and the sum of p and q is an integer from 1 to 3.

14. A composition according to any one of claims 1 to 13, wherein said quinoline derivative has formula II:

$$\prod_{R_2}^{(R_1)_q}$$

wherein

R<sub>1</sub>' is selected from -Cl, C<sub>1</sub>-C<sub>3</sub> alkyloxy, and -CF<sub>3</sub>;

R<sub>2</sub> is selected from -NH(R<sub>3</sub>), and -C(OH)(R<sub>3</sub>), wherein R<sub>3</sub> is C<sub>3</sub>-C<sub>6</sub> alkyl substituted with 1 to 3 substituents selected from C<sub>1</sub>-C<sub>2</sub> alkyl, ethenyl, and -NH<sub>2</sub>, and wherein said -NH<sub>2</sub> is either optionally substituted with one or two groups selected from ethyl and hydroxyethyl or the nitrogen atom of said -NH<sub>2</sub> is connected with 1 or 2 carbon atoms of said C<sub>3</sub>-C<sub>6</sub> alkyl or C<sub>1</sub>-C<sub>2</sub> alkyl, possibly forming bicyclic structure, and

q is 1 or 2.

15. A composition according to any one of claims 1 to 14, comprising a stereoisomer, or a mixture of stereoisomers, of a quinoline derivative according to claim 1.

WO 2005/069731 -22- PCT/IL2005/000078

- 16. A composition according to claim 15, wherein the compound of formula I is selected from quinine, quinidine, hydroxychloroquine, and a salt thereof.
- 17. A composition according to any one of claims 1 to 16, wherein said mucositis comprises canker sores associated with aphtha minor, aphtha major, recurrent aphthous ulcers, or recurrent aphthous stomatitis.
- 18. A composition according to claim 17, wherein said mucositis is accompanied by a secondary infection.
- 19. A composition according to any one of claims 1 to 18, wherein said quinoline derivative or said pharmaceutically acceptable salt thereof has a concentration of from 0.04 mg/ml to 10 mg/ml.
- 20. A composition according to claim 19, wherein said quinoline derivative or said pharmaceutically acceptable salt thereof has a concentration of from 0.05 mg/ml to 0.120 mg/ml.
- 21. A method for ameliorating, treating, and preventing an oral mucosa disorder, comprising
  - i) providing a quinoline derivative of formula I as defined in claim<sup>1</sup>
    or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;
  - ii) optionally providing an antiseptic;
  - iii) preparing a one-component formulation comprising said quinoline derivative; or alternatively two-component composition comprising either two formulations containing separately said antiseptic and said quinoline derivative (or its isomer or salt), or one formulation comprising a mixture of said antiseptic and quinoline derivative in solution or suspension; wherein said formulations may further comprise constituents adjusting the consistency, stability, and olfactory properties, and optionally an additional active substances

- selected from analgesic, anti-inflammatory, antiviral, antibacterial, antifungal, antiseptic, and antineoplastic; and
- iv) administering said formulation or formulations to a patient in need of the treatment, wherein the two components in said twocomponent composition may be administered simultaneously or subsequently.
- 22. The method of claim 21, wherein said administration of said formulation or formulations comprises rinsing, spraying, and applying ointment or adhesive patch.
- 23. The method of claim 21, wherein said administration comprises rinsing with said formulation or formulations, and swallowing the formulation which comprises said quinoline derivative but not said antiseptic.
- 24. The method of claim 21, wherein said mucosa disorder is associated with aphtha, and wherein said administration comprises rinsing mouth several times a day.
- 25. The method of claim 22, wherein said rinsing comprises two liquids, one comprising an antiseptic, and the other a compound of formula I.
- 26. The method of claim 21, wherein said antiseptic is chlorhexidine in an alcohol-free water solution.
- 27. The method of claim 21, wherein said compound of formula I is selected from quinine, quinidine, hydroxychloroquine, and a salt thereof.